Endocrine Pharmacology Practice Questions

Q: Which of the following is NOT an adverse effect of growth hormone therapy?

Hypoglycemia. Growth hormone (GH) therapy is primarily used for GH deficiency, Turner syndrome, and Prader-Willi syndrome. Understanding its metabolic and structural effects is crucial for the NEET-PG exam.### Why Hypoglycemia is the Correct AnswerGrowth hormone is a **diabetogenic hormone**. It antagonizes the action of insulin, decreases peripheral glucose uptake, and increases hepatic gluconeogenesis. Therefore, the adverse effect associated with GH therapy is **Hyperglycemia** [1], not hypoglycemia. Chronic use can lead to glucose intolerance and overt diabetes mellitus.### Explanation of Incorrect Options* **Carpal Tunnel Syndrome:** GH stimulates the growth of connective tissue and promotes fluid retention (sodium/water). This can lead to edema and compression of the median nerve within the carpal tunnel [1].* **Intracranial Hypertension (Pseudotumor Cerebri):** This is a rare but classic side effect, especially in children. It presents with headache, visual changes, and papilledema, usually occurring early in treatment [1, 2].* **Slipped Capital Femoral Epiphysis (SCFE):** Rapid longitudinal bone growth induced by GH can put mechanical stress on the growth plate, leading to displacement of the femoral head [1].### High-Yield Clinical Pearls for NEET-PG* **Metabolic Effect:** GH increases lean body mass (anabolic) and decreases fat mass (lipolytic).* **IGF-1:** Most of the growth-promoting effects of GH are mediated by **Insulin-like Growth Factor-1 (IGF-1)**, produced mainly in the liver.* **Contraindication:** GH therapy is contraindicated in patients with active malignancy (due to its proliferative effects) and in those with closed epiphyses (if used for height).* **Pancreatitis:** Though rare, GH therapy has been associated with an increased risk of acute pancreatitis [1].

Q: What is the medical management of insulinoma?

Diazoxide. **Explanation:** **Insulinoma** is a rare neuroendocrine tumor of the pancreas that secretes excessive insulin, leading to severe fasting hypoglycemia. While surgical resection is the definitive treatment, medical management is required for patients who are non-surgical candidates or have metastatic disease. **Why Diazoxide is the Correct Answer:** Diazoxide is the drug of choice for the medical management of insulinoma. It acts as a **K+ channel opener** (specifically the ATP-sensitive potassium channels) in the pancreatic beta cells. By keeping these channels open, it hyperpolarizes the cell membrane, thereby inhibiting the release of insulin. Additionally, it stimulates glucose release from the liver and enhances catecholamine response, collectively raising blood glucose levels. **Analysis of Incorrect Options:** * **Octreotide:** While this somatostatin analog can inhibit insulin release, its effect is unpredictable. In some patients, it may also inhibit Growth Hormone and Glucagon, potentially worsening hypoglycemia. It is generally considered a second-line agent. * **Streptozotocin:** This is a nitrosourea alkylating agent that is specifically cytotoxic to pancreatic beta cells. It is used for **chemical ablation** in malignant insulinomas rather than routine medical management of symptoms. * **Somatomedin:** Also known as Insulin-like Growth Factor (IGF), it has insulin-like effects and would worsen hypoglycemia. It has no role in treating insulinoma. **High-Yield Clinical Pearls for NEET-PG:** * **Whipple’s Triad:** Symptoms of hypoglycemia, low plasma glucose (<50 mg/dL), and relief of symptoms after glucose administration (diagnostic for insulinoma). * **Diazoxide Side Effect:** A notable side effect is **sodium and water retention** (often requiring diuretics) and **hypertrichosis** (excessive hair growth). * **Alternative:** If Diazoxide fails, **Everolimus** (an mTOR inhibitor) is increasingly used for malignant insulinomas.

Q: Which of the following agents does NOT decrease bone resorption in osteoporosis?

Teriparatide. **Explanation:** The management of osteoporosis involves two main classes of drugs: **Antiresorptive agents** (which inhibit osteoclast activity) and **Anabolic agents** (which stimulate osteoblast activity to form new bone). **Why Teriparatide is the correct answer:** Teriparatide is a recombinant form of human **Parathyroid Hormone (PTH 1-34)**. Unlike continuous high levels of endogenous PTH which cause bone loss, **intermittent (once-daily)** administration of Teriparatide stimulates **osteoblasts** more than osteoclasts. This leads to a net increase in bone mineral density (BMD) and improved bone architecture. Therefore, it is an **anabolic agent**, not an antiresorptive one. **Analysis of Incorrect Options:** * **Alendronate & Etidronate (Bisphosphonates):** These are the prototypical **antiresorptive** agents. They concentrate at sites of active remodeling and inhibit the enzyme *farnesyl pyrophosphate synthase* in osteoclasts, leading to osteoclast apoptosis and decreased bone resorption. * **Strontium Ranelate:** This agent has a **dual mechanism of action**. It both increases bone formation (anabolic) and decreases bone resorption (antiresorptive). Since it does decrease resorption, it is not the correct choice for this "NOT" question. **High-Yield Clinical Pearls for NEET-PG:** * **Teriparatide Limit:** Due to a theoretical risk of **Osteosarcoma** (seen in rat studies), its use is typically limited to a maximum of 2 years. * **Denosumab:** A monoclonal antibody against **RANKL**; it is a potent antiresorptive agent. * **Bisphosphonates Side Effect:** The most common is esophageal irritation; the most "high-yield" for exams are **Osteonecrosis of the Jaw (ONJ)** and **Atypical Subtrochanteric Fractures** with long-term use. * **First-line:** Bisphosphonates remain the first-line treatment for most patients with osteoporosis.

Q: Which one of the following is an adverse effect associated with combined oral contraceptives?

Cerebral stroke. **Explanation:** The correct answer is **Cerebral stroke**. Combined Oral Contraceptive Pills (COCPs) contain both estrogen (usually Ethinyl Estradiol) and progestogen. The estrogen component increases the hepatic synthesis of clotting factors (II, VII, IX, X) and decreases antithrombin III, leading to a **hypercoagulable state**. This significantly increases the risk of thromboembolic phenomena, including deep vein thrombosis (DVT), pulmonary embolism, and arterial thrombosis leading to myocardial infarction or **ischemic cerebral stroke**. The risk is further potentiated in women who smoke, are over 35 years old, or have underlying hypertension. **Analysis of Incorrect Options:** * **B. Aggravation of asthma:** COCPs do not typically aggravate asthma. In fact, some studies suggest that hormonal stabilization may improve premenstrual asthma exacerbations in certain patients. * **C. Peripheral neuropathy:** There is no established clinical link between COCP use and peripheral neuropathy. * **D. Nephrotic syndrome:** COCPs are not a cause of nephrotic syndrome. However, they are generally avoided in patients with severe renal disease due to the associated cardiovascular risks and potential for fluid retention. **High-Yield NEET-PG Pearls:** * **Most common side effect:** Breakthrough bleeding (spotting), especially in the first few months. * **Most serious side effect:** Venous Thromboembolism (VTE). * **Protective effects:** COCPs significantly reduce the risk of **Ovarian cancer** (by 50%) and **Endometrial cancer** (by 50%). They also reduce the risk of Benign Breast Disease and Pelvic Inflammatory Disease (PID). * **WHO Category 4 (Absolute Contraindications):** Smokers >35 years (>15 cigarettes/day), history of VTE/Stroke, Migraine with aura, and Breast cancer.

Q: Which one of the following statements about the mechanism of action of Metformin is true?

Enhances glucose uptake by skeletal muscle. **Explanation:** Metformin is a **Biguanide** and is currently the first-line oral hypoglycemic agent for Type 2 Diabetes Mellitus. Unlike sulfonylureas, it does not act by increasing insulin secretion; instead, it is an **insulin sensitizer**. **Why Option C is Correct:** The primary mechanism of Metformin involves the activation of **AMP-activated protein kinase (AMPK)**. In skeletal muscle, this activation triggers the translocation of **GLUT-4 transporters** to the cell membrane, significantly enhancing peripheral glucose uptake and utilization. This reduces insulin resistance without causing weight gain. **Why Other Options are Incorrect:** * **Options A & B:** Metformin **inhibits** hepatic gluconeogenesis and glycogenolysis. By suppressing these processes, it reduces the excessive hepatic glucose output typically seen in diabetic patients. * **Option D:** This describes the mechanism of **Sulfonylureas** (e.g., Glipizide) and **Meglitinides**. Metformin is "euglycemic"; it does not stimulate insulin release from pancreatic beta cells, which is why it carries a very low risk of hypoglycemia when used as monotherapy. **High-Yield NEET-PG Pearls:** 1. **Drug of Choice:** First-line for T2DM, especially in obese patients (weight neutral/loss). 2. **PCOS:** Used to improve ovulation and menstrual regularity by reducing insulin resistance. 3. **Side Effects:** Most common are GI upset (diarrhea, abdominal pain). The most serious, though rare, is **Lactic Acidosis** (contraindicated in renal failure, Cr >1.5 mg/dL). 4. **Vitamin Deficiency:** Long-term use can lead to **Vitamin B12 deficiency** due to malabsorption in the terminal ileum.

Question 1

Which of the following is NOT an adverse effect of growth hormone therapy?

Accepted Answer

Hypoglycemia

Answer

Carpal tunnel syndrome

Answer

Intracranial hypertension

Answer

Slipped femoral epiphysis

Question 2

What is the medical management of insulinoma?

Accepted Answer

Diazoxide

Answer

Octreotide

Answer

Streptozotocin

Answer

Somatomedin

Question 3

Which of the following agents does NOT decrease bone resorption in osteoporosis?

Accepted Answer

Teriparatide

Answer

Alendronate

Answer

Etidronate

Answer

Strontium

Question 4

Which one of the following is an adverse effect associated with combined oral contraceptives?

Accepted Answer

Cerebral stroke

Answer

Aggravation of asthma

Answer

Peripheral neuropathy

Answer

Nephrotic syndrome

Question 5

Which one of the following statements about the mechanism of action of Metformin is true?

Accepted Answer

Enhances glucose uptake by skeletal muscle

Answer

Stimulates glycogenolysis

Answer

Stimulates hepatic gluconeogenesis

Answer

Releases insulin from beta cells of the pancreas

Question 6

A 35-year-old woman presents with swelling of the small joints of the hands. On examination, swan neck deformity is present. Labs show elevated rheumatoid factor levels and high anti-CCP levels. She is diagnosed with rheumatoid arthritis and started on steroids for a short duration. What is the mechanism by which steroids reduce inflammation?

Accepted Answer

Inhibition of phospholipase A2

Answer

Inhibition of cyclo-oxygenase

Answer

Inhibition of lipoprotein lipase activity

Answer

Inhibition of lipogenase

Question 7

A patient with chronic kidney disease stage 4 is receiving insulin therapy. What adjustment in insulin dosage is required?

Accepted Answer

Decrease dose of insulin

Answer

Increase dose of insulin

Answer

Variable dose

Answer

No alteration in dose

Question 8

Which of the following statements about Afrezza is incorrect?

Accepted Answer

It has a longer duration of action than injected insulin analogues.

Answer

It is an inhaled form of insulin.

Answer

It should be avoided in smokers.

Answer

Adverse effects include cough and throat irritation.

Question 9

What is the drug of choice for post-menopausal osteoporosis?

Accepted Answer

Alendronate

Answer

Raloxifene

Answer

Tamoxifene

Answer

Estrogen

Question 10

What is the difference between carbimazole and propylthiouracil?

Accepted Answer

Carbimazole does not inhibit the peripheral conversion of T4 to T3.

Answer

Carbimazole is less potent.

Answer

Carbimazole is shorter acting.

Answer

Carbimazole does not produce an active metabolite.

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?